Data for 479 patients were analyzed to assess the impact of methicillin resistance on the outcomes of patients with Staphylococcus aureus surgical site infections (SSIs). Patients infected with methicillin-resistant S. aureus (MRSA) had a greater 90-day mortality rate than did patients infected with methicillin-susceptible S. aureus (MSSA; adjusted odds ratio, 3.4; 95% confidence interval, 1.
found higher costs in patients with a variety of MRSA infections compared with uninfected control subjects [27, 28] .
The authors of one study reported an increase in length of hospital stay but no increase in the mortality rate among surgical patients infected with MRSA compared with patients infected with MSSA [8] . Mekontso-Dessap et al. [12] demonstrated an increased risk for mortality and longer duration of hospitalization for patients with SSI due to MRSA compared with patients with SSI due to MSSA. To our knowledge, no studies have addressed the attributable impact of methicillin resistance on hospital costs among patients with SSI. The objective of this study was to evaluate the attributable impact of methicillin resistance on clinical outcomes and hospital charges in patients with S. aureus SSI.
METHODS

Hospital setting and study design.
This study included patients undergoing surgery at Duke University Medical Center (Durham, NC), a 900-bed tertiary care academic medical center, and Durham Regional Hospital (Durham, NC), a 350-bed community hospital. Both hospitals had active infectioncontrol surveillance programs for SSI during the study period, and both hospitals used National Nosocomial Infection Surveillance (NNIS) criteria for the diagnosis of SSI [29] . This study was approved by the Duke University Medical Center Institutional Review Board.
This was a cohort study. All patients who underwent surgical procedures for which SSI surveillance was conducted during the period of 1 January 1994 through 30 November 2000 were prospectively identified, as was the subset of patients with SSI and positive cultures for S. aureus. Patients were included in the cohort if they were identified as having a SSI at admission for their original surgical procedure or if they were readmitted with a SSI after their primary surgical admission. The intent was to include only the first episode of SSI for each patient; however, no patient experienced 11 episode.
Three patient groups were studied: (1) patients with SSI due to MRSA, (2) patients with SSI due to MSSA, and (3) uninfected control patients. Control patients were randomly selected from the group of uninfected patients who underwent the same type of surgical procedure and who had the same calendar years of surgery as the case patients. The number of uninfected control subjects selected for each procedure equaled the number of patients with SSI due to either MSSA or MRSA, whichever number was larger. As a result, the total number of patients selected for the control group was greater than the total number of patients in either the MRSA or MSSA SSI groups.
Data collection and microbiological characteristics. Data that were collected prospectively included patient demographic characteristics, date and type of surgical procedure, and NNIS risk index variables (i.e., the American Society of Anesthesiologists (ASA) score [30] , duration of surgery, and wound class) [31] . For patients who developed an SSI due to S. aureus, microbiological data, including date on which samples were obtained for culture, site of culture specimen, and type of pathogen recovered, were recorded. The date of onset of SSI was defined as the collection date for incision or organ-space samples for which the initial culture was positive for S. aureus. Limb amputations and saphenous vein graft harvest site infections were excluded. All infections were deep or organ-space infections; superficial infections were excluded [29] .
Additional data were retrospectively obtained from the hospital billing and admission-discharge-transfer databases. Data obtained from hospital billing records included comorbid conditions (identified by the codes of the International Classification of Diseases, Ninth Revision [ICD-9]), dates of hospitalization and intensive care unit (ICU) admission, and whether a patient had been transferred from another hospital. In addition to the use of ICD-9 codes, we used billing data to identify patients with diabetes mellitus and noted the presence of intravenous insulin drips and glucometer use.
Data collected pertaining to the 90-day postoperative outcomes included mortality (in-hospital and outpatient; data were obtained from patient charts and the United States Social Security Death Index [http://www.ancestry.com]), total hospital days (including readmissions), and hospital charges, including charges for readmissions. Charges were used as a surrogate for cost because direct cost data were not available; hereafter, "hospital cost" will refer to hospital charges. All data were collated into a single database (Access 97; Microsoft).
Microbiological and antimicrobial susceptibility results were obtained from the clinical microbiology database. S. aureus isolates were identified by growth of coagulase-and catalasepositive gram-positive cocci. Methicillin resistance was determined by lack of inhibition of growth by an oxacillin disc on mannitol salt agar, according to the criteria of the National Committee for Clinical Laboratory Standards [32] .
Statistical analysis. Multivariate analyses were performed to assess the impact of methicillin resistance on 90-day mortality rate, total hospital days, and hospital costs (the latter were discounted at a 3% annual rate, with the year 2000 serving as the reference year). Risk models for mortality were derived by logistic regression. Risk models for hospital costs and total hospital days were derived by linear regression after these outcomes were log transformed. Variables from bivariate analysis with a P value of ! .20 were included as candidate variables for the risk models. Risk factor models were derived by a stepwise selection procedure. All predictors were checked for confounding and collinearity. If the addition of a confounding variable affected the b coefficient for the effect measure of a selected candidate variable by 110%, it was left in the model. All tests were 2 tailed, with Pр .05 considered to be statistically significant.
Adjusted mean attributable outcomes per SSI for methicillin resistance were calculated as follows for total hospital days and charges. The b coefficient was obtained from the corresponding linear regression model. Mean attributable charges are used as an example: mean attributable charges per (mean SSI p [ charges for patients with MSSA SSI inverse log of the b ) ϫ ( coefficient for adjusted MRSA variable mean charges for )] Ϫ ( patients with MSSA SSI).
RESULTS
During the period of 1 January 1994 through 30 November 2000, 173 patients with SSI due to MSSA and 127 patients with SSI due to MRSA were identified, and 193 uninfected control patients were selected. A total of 14 patients with SSI (8 patients with MSSA SSI and 6 with MRSA SSI) were excluded from analysis because of incomplete or unavailable hospital billing data. A total of 165 patients with SSI due to MSSA and 121 patients with SSI due to MRSA had complete data available and were included in the analysis. No patients who were excluded died during the 90-day postoperative period. No patient had 11 SSI due to S. aureus. [3.8%] ). Overall, the distribution of type of surgical procedure was similar among the 3 study groups, although compared with the patients with MSSA SSI, there were fewer patients who acquired MRSA infection after undergoing orthopedic procedures (table 1). All SSIs that occurred after cardiothoracic procedures were classified as mediastinitis by NNIS criteria [29] .
Patient demographic characteristics are shown in ). Seventeen (68.0%) of the P ! .001 25 patients with MRSA SSI who died and 7 (63.6%) of the 11 patients with MSSA SSI who died had mediastinitis. In addition to MRSA SSI, other predictors of mortality among the S. aureus SSI group included increasing age, ASA score, duration of surgery, NNIS risk index, and length of hospital stay before infection (table 3) . On multivariate analysis, after adjusting for age, an ASA score of 4 (there were no patients with an ASA score of 5), and surgical duration greater than the median time for the entire cohort, the independent impact of methicillin resistance on mortality remained unchanged (OR, 3.4; 95% CI, 1.5-7.2;
). P p .003 Hospital days. Uninfected patients had significantly fewer total hospital days after surgery (median, 5 days) than did patients with SSI due to MSSA (median, 14 days;
) and P ! .001 patients with MRSA SSI (median, 23 days;
; table 2).
The median number of days of hospitalization after infection (i.e., the culture date) was 5 days greater for patients with SSI due to MRSA (median, 15 days; mean, 22.0 days) than for patients with SSI due to MSSA (median, 10 days; mean, 13.2 days;
), as was the number of days spent in the ICU P ! .001 (median number of days in the ICU after infection for patients with MRSA SSI, 0 [mean, 5.1; interquartile range, 0-3]; median number of days in the ICU for patients with MSSA SSI, 0 [mean, 1.9; interquartile range, 0-1];
). Increasing age, P p .02 ASA score, duration of surgery, NNIS risk index, length of stay before culture, length of ICU stay before culture, receipt of treatment at Duke University Medical Center, and the presence of diabetes, hypertension, pulmonary disease, and renal disease were also associated with an increased number of hospital days after infection. After controlling for ASA score, hospital, surgical duration, diabetes, renal disease, and length of stay before infection, the association between methicillin resistance and an increase in total hospital days (1.20-fold increase; 2.6 additional hospital days after infection per case of S. aureus SSI) among patients with S. aureus SSI was not found to be significant ( ) . P p .11
Hospital costs. The median hospital cost for uninfected control subjects was $29,455 (mean, $34,395) (table 2). Hospital costs were significantly lower for control subjects than for patients with SSI due to either MSSA or MRSA ( ). The P ! .001 median hospital cost was ∼$40,000 greater for patients with SSI due to MRSA (median, $92,363; mean, $118,415) than for patients with SSI due to MSSA (median, $52,791; mean, $73,165;
; table 2). Other predictors of increased hos-P ! .001 pital cost included increasing age, ASA score, duration of surgery, NNIS risk index, length of hospital stay before samples were obtained for culture, length of ICU stay before culture, receipt of care at Duke University Medical Center, and the presence of diabetes, hypertension, peripheral vascular disease, pulmonary disease, or renal disease. After adjusting for duration of surgery, hospital, length of hospitalization before infection, length of ICU stay before infection, renal disease, and diabetes mellitus, methicillin resistance was found to be associated with a 1.19-fold increase in the median hospital cost ( ). The P p .03 mean cost per case attributable to methicillin resistance was $13,901 per case of S. aureus SSI. Costs were not confounded by year of surgery. For all outcomes, analyses restricted to the orthopedic and cardiothoracic subgroups yielded similar results (data not shown).
DISCUSSION
In this study, patients with MRSA SSI were found to be at greater risk for mortality and increased hospital costs than patients were with MSSA SSI. Compared with uninfected control subjects, patients with MRSA SSI also had longer durations of hospitalization. Studying a large cohort of patients undergoing a variety of surgical procedures allowed us to evaluate the independent contribution of methicillin resistance on adverse outcomes among patients with SSI due to S. aureus. Only 1 published article has addressed the attributable impact of the presence of MRSA on the clinical outcomes of patients with SSI [12] . The authors reported similar findings regarding the independent contribution of methicillin resistance to increased mortality and prolonged hospitalization among patients with mediastinitis due to S. aureus.
We found that the presence of MRSA in a surgical wound was associated with a 112-fold increase in the 90-day postoperative mortality rate compared with the rate for patients without SSI; compared with patients who had SSI due to MSSA, the adjusted risk of death was increased 13 fold. We observed that patients with SSI due to MRSA had greater hospital costs than did patients with SSI due to MSSA (adjusted mean attributable hospital cost per SSI, $13,901). Although patients with SSI due to MRSA had longer durations of hospitalization after surgery than did patients with SSI due to MSSA, this did not reach statistical significance. This was surprising, because increased hospital costs usually correlate with an increased length of hospital stay. One explanation for this result may be the fact that patients with MRSA infections had longer lengths of ICU stay after infection than did patients with MSSA infection. Stays in the ICU are costly, and the increased number of ICU days among patients with MRSA SSI probably accounted for the increased hospital costs, at least in part.
Patients who received care at Duke University Medical Center had higher hospital costs and longer durations of hospital stay than did patients who received care at Durham Regional Hospital. This probably relates to a greater severity of underlying illness among the surgical population at Duke University Medical Center; ASA scores were higher among patients at the Duke University Medical Center than among those who received care at Durham Regional Hospital.
Although data regarding the contribution of methicillin resistance to increased mortality are conflicting, our results are consistent with those of other investigators, including a recent meta-analysis of patients with S. aureus bacteremia in which methicillin resistance was associated with a 2-fold increase in the mortality rate [33] . The majority of deaths in our cohort occurred among patients with mediastinitis. Vancomycin is less bactericidal against MSSA than are b-lactam agents, vancomycin therapy has been associated with clinical failure in the treatment of MSSA infection, and vancomycin has been shown to have suboptimal sternal bone penetration [15, [34] [35] [36] . Thus, therapy for patients with MRSA infection, which usually requires vancomycin, would logically be expected to be less effective than b-lactam therapy for patients with MSSA infection.
There are some limitations to this study. Our results may underestimate the impact of methicillin resistance on outcomes, because some patients (especially those with MSSA infections) may have been treated as outpatients with oral antibiotics. Another limitation is that, if patients were readmitted to another hospital for diagnosis and treatment of SSI, they would not have been included in the study cohort. Daily hospital costs were not available, so attributable costs that occurred after infection could not be directly analyzed. As an alternative, overall hospital costs were modeled, and we controlled for length of stay before S. aureus infection in the model. We did not study the different types of antimicrobial therapy used or the time from infection to debridement, because these were not objectives of this study.
To our knowledge, this is the largest cohort used to analyze attributable mortality and length of stay related to methicillin resistance among patients with S. aureus SSI, and this is also the first study to investigate attributable hospital costs among this population. Because a high percentage of SSIs are diagnosed at readmission, all hospital readmissions occurring in the 90-day postoperative period were included in the analysis. Other strengths of the study include the fact that attempts were made to control for the severity of comorbid illnesses and hospital events before the diagnosis of infection.
MRSA SSIs are responsible for adverse patient outcomes and the use of large amounts of additional hospital resources. During the cohort period, among patients with S. aureus SSI, methicillin resistance was responsible for a total excess cost of $240,289 per year at the 2 study institutions. Interventions geared toward the prevention of MRSA SSI should be pursued.
The adverse clinical and economic outcomes associated with MRSA SSI relate to the complicated nature of MRSA infections, the availability of only suboptimal antimicrobial agents to treat this pathogen, and the clinical complexities of patients who become infected with MRSA. Preoperative antimicrobial prophylaxis typically does not include an agent active against MRSA. Vancomycin prophylaxis has been modeled for use in coronaryartery bypass graft surgery, and the results were encouraging [37] . For hospitals with appreciable rates of MRSA SSI, risk factors for MRSA SSI should be evaluated, and preoperative antimicrobial prophylaxis with an agent active against MRSA should be considered for high-risk patients. Efforts should also be made to aggressively treat MRSA SSI with debridement and to rapidly introduce effective antimicrobial therapy.
